Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Miller, K. D.
Right arrow Articles by Sledge, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, K. D.
Right arrow Articles by Sledge, G. W.
Related Collections
Right arrow 2003 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:20-28, 2003
© 2003 European Society for Medical Oncology

The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era

K. D. Miller+, C. J. Sweeney and G. W. Sledge

Division of Hematology and Oncology, Indiana University, Indianapolis, USA

Received 18 July 2002; accepted 13 September 2002

Abstract

If your Snark be a Snark, that is right:

Fetch it home by all means—you may serve it with greens,

And it’s handy for striking a light . . .

"But oh, beamish nephew, beware of the day,

If your Snark be a Boojum! For then

You will softly and suddenly vanish away,

And never be met with again!"

Lewis Carroll

The Hunting of the Snark

Key words: angiogenesis, drug resistance, endothelial cells, growth factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Kuhnert, B. Y. Y. Tam, B. Sennino, J. T. Gray, J. Yuan, A. Jocson, N. R. Nayak, R. C. Mulligan, D. M. McDonald, and C. J. Kuo
Soluble receptor-mediated selective inhibition of VEGFR and PDGFR{beta} signaling during physiologic and tumor angiogenesis
PNAS, July 22, 2008; 105(29): 10185 - 10190.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. S. Kerbel
Tumor Angiogenesis
N. Engl. J. Med., May 8, 2008; 358(19): 2039 - 2049.
[Full Text] [PDF]

Home page
 NEJMHome page
K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh, E. A. Perez, T. Shenkier, D. Cella, and N. E. Davidson
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
N. Engl. J. Med., December 27, 2007; 357(26): 2666 - 2676.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. W. J. van der Schaft, R. E. B. Seftor, E. A. Seftor, A. R. Hess, L. M. Gruman, D. A. Kirschmann, Y. Yokoyama, A. W. Griffioen, and M. J. C. Hendrix
Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells
J Natl Cancer Inst, October 6, 2004; 96(19): 1473 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Laurent, S. de Bouard, J.-S. Guillamo, C. Christov, R. Zini, H. Jouault, P. Andre, V. Lotteau, and M. Peschanski
Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo
Mol. Cancer Ther., February 1, 2004; 3(2): 129 - 136.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Kerr
A little citadel of light in a malignant sea of darkness
Ann. Onc., January 1, 2004; 15(1): 1 - 2.
[Full Text] [PDF]

Home page
 Ann OncolHome page
B. Vincenzi, D. Santini, L. Rocci, and G. Tonini
Bisphosphonates: new antiangiogenic molecules in cancer treatment?
Ann. Onc., May 1, 2003; 14(5): 806 - 807.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.